Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/26199
Title: | Novel Approach to Risk Stratification in Left Ventricular Non-Compaction Using A Combined Cardiac Imaging and Plasma Biomarker Approach. | Austin Authors: | Ramchand, Jay ;Podugu, Pooja;Obuchowski, Nancy;Harb, Serge C;Chetrit, Michael;Milinovich, Alex;Griffin, Brian;Burrell, Louise M ;Wilson Tang, W H;Kwon, Deborah H;Flamm, Scott D | Affiliation: | Medicine (University of Melbourne) Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH Imaging Institute, Cleveland Clinic, Cleveland, OH |
Issue Date: | 20-Apr-2021 | Date: | 2021-04-09 | Publication information: | Journal of the American Heart Association 2021; 10(8): e019209 | Abstract: | Background Left ventricular non-compaction remains a poorly described entity, which has led to challenges of overdiagnosis. We aimed to evaluate if the presence of a thin compacted myocardial layer portends poorer outcomes in individuals meeting cardiac magnetic resonance criteria for left ventricular non-compaction . Methods and Results This was an observational, retrospective cohort study involving individuals selected from the Cleveland Clinic Foundation cardiac magnetic resonance database (N=26 531). Between 2000 and 2018, 328 individuals ≥12 years, with left ventricular non-compaction or excessive trabeculations based on the cardiac magnetic resonance Petersen criteria were included. The cohort comprised 42% women, mean age 43 years. We assessed the predictive ability of myocardial thinning for the primary composite end point of major adverse cardiac events (composite of all-cause mortality, heart failure hospitalization, left ventricular assist device implantation/heart transplant, ventricular tachycardia, or ischemic stroke). At mean follow-up of 3.1 years, major adverse cardiac events occurred in 102 (31%) patients. After adjusting for comorbidities, the risk of major adverse cardiac events was nearly doubled in the presence of significant compacted myocardial thinning (hazard ratio [HR], 1.88 [95% CI, 1.18‒3.00]; P=0.016), tripled in the presence of elevated plasma B-type natriuretic peptide (HR, 3.29 [95% CI, 1.52‒7.11]; P=0.006), and increased by 5% for every 10-unit increase in left ventricular end-systolic volume (HR, 1.01 [95% CI, 1.00‒1.01]; P=0.041). Conclusions The risk of adverse clinical events is increased in the presence of significant compacted myocardial thinning, an elevated B-type natriuretic peptide or increased left ventricular dimensions. The combination of these markers may enhance risk assessment to minimize left ventricular non-compaction overdiagnosis whilst facilitating appropriate diagnoses in those with true disease. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/26199 | DOI: | 10.1161/JAHA.120.019209 | Journal: | Journal of the American Heart Association | PubMed URL: | 33834849 | Type: | Journal Article | Subjects: | biomarkers cardiac magnetic resonance cardiomyopathy echocardiography non‐compaction |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.